Stockscreener 앱 받기
10.91
35.36%
2.85
시장 영업 전:
10.59
-0.32
-2.93%
전일 마감가:
$8.06
열려 있는:
$8.22
하루 거래량:
2.97M
Relative Volume:
36.71
시가총액:
$3.79M
수익:
$10.48M
순이익/손실:
$-37.74M
주가수익비율:
-0.6741
EPS:
-16.1846
순현금흐름:
$-29.03M
1주 성능:
+98.00%
1개월 성능:
+101.66%
6개월 성능:
-60.68%
1년 성능:
-95.72%
1일 변동 폭
$8.22
$15.48
1주일 범위
$5.52
$15.48
52주 변동 폭
$4.02
$540.00
재규어 헬스 Stock (JAGX) Company Profile
명칭
Jaguar Health Inc
전화
415-371-8300
주소
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
JAGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
10.91 | 3.79M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
재규어 헬스 Stock (JAGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
재규어 헬스 주식(JAGX)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Jaguar Health's (JAGX) Crofelemer Shows Promise in Breast Cancer Subgroup - GuruFocus
Jaguar Health Presents at Elite Ped-GI Congress 2025 - TipRanks
Jaguar Health (JAGX) Reports Progress in Rare Disease Drug Trial - GuruFocus
Jaguar Health's (JAGX) Crofelemer Trial Shows Promise for Rare Disorders | JAGX Stock News - GuruFocus
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress | JAGX Stock News - GuruFocus
First-Ever MVID Treatment? Crucial Trial Data for Orphan Drug Crofelemer Coming to Elite Congress - Stock Titan
Jaguar Health to present results from OnTarget study in breast cancer patients - Yahoo Finance
Jaguar Health to discuss breast cancer treatment with FDA By Investing.com - Investing.com South Africa
Jaguar Health (JAGX) Advances OnTarget Study with Key Presentati - GuruFocus
Jaguar Health to discuss breast cancer treatment with FDA - Investing.com
Jaguar Health Announces Significant Results in Breast Cancer Pat - GuruFocus
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting | JAGX Stock News - GuruFocus
Game-Changing Results: New Cancer Drug Shows Remarkable Success in Breast Cancer Patients - Stock Titan
Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2024 Earnings Call Transcript - MSN
Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea - ACCESS Newswire
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting - GuruFocus
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product - markets.businessinsider.com
Revolutionary Pain Relief: New FDA-Approved Treatment Transforms Cancer Care Experience - Stock Titan
Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer - ACCESS Newswire
Jaguar Health (NASDAQ:JAGX) Shares Cross Below Two Hundred Day Moving Average – What’s Next? - Defense World
Jaguar Animal Health Secures $3.448M in Private Placement - TipRanks
Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials - ACCESS Newswire
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire
Jaguar Health Expands Workforce: New Stock Grants Signal Growth Strategy - Stock Titan
Jaguar Health outlines key Q2 2025 catalysts for crofelemer programs - MSN
Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product - ACCESS Newswire
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates - ACCESS Newswire
Jaguar Health completes $3.4 million private placement By Investing.com - Investing.com South Africa
Jaguar Health completes $3.4 million private placement - Investing.com
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Jaguar Health Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Jaguar Health Advances Plant-Based Pharmaceuticals - TipRanks
Jaguar Health’s Earnings Call: Growth Amid Challenges - TipRanks
Earnings call transcript: Jaguar Health sees revenue growth in Q4 2024 - Investing.com Canada
JAGX stock plunges to 52-week low, touches $4.9 amid steep decline By Investing.com - Investing.com South Africa
JAGX stock plunges to 52-week low, touches $4.9 amid steep decline - Investing.com Australia
Earnings call transcript: Jaguar Health sees revenue growth in Q4 2024 By Investing.com - Investing.com South Africa
재규어 헬스 (JAGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):